Table 1.
Study population information.
Participant | Age (years) | Sex | BMI | Trial | Challenge agent | Dose (viable p/mL) | Day of post inoculation imaging | Parasitemia at imaging (p/mL) |
---|---|---|---|---|---|---|---|---|
1 | 20 | F | 29.5 | Collins et al. 202018 | Pv | 564 | 9 | 29,097 |
2 | 23 | M | 22.9 | Collins et al. 202018 | Pv | 564 | 9 | 5818 |
3 | 20 | M | 22.0 | Collins et al. 202018 | Pv | 564 | 9 | 6042 |
4 | 19 | M | 28.5 | Gaur et al. 202019 | Pf | 2800 | 7 | 1427 |
5 | 22 | M | 22.0 | Gaur et al. 202019 | Pf | 2800 | 7 | 998 |
6 | 19 | M | 19.7 | Woolley et al. 202120 | Pf | 2800 | 11 | 43,224 |
7 | 19 | M | 24.2 | Woolley et al. 202120 | Pf | 2800 | 10 | 99,134 |
Parasitemia at imaging: estimated by interpolating the linear rate of change between the closest log-transformed parasitemia measurements.
BMI body mass index, Pv P. vivax, Pf P. falciparum.